Fig. 1
Construction of sTNFRII-MSC. a Schematic representation of the GV358 lentivirus vector. Transcription of the sTNFRII-Fc, EGFP and Puror gene is initiated from the 5’ LTR. The vector is not drawn to scale. b The morphology and transfection efficiency of UC-MSCs. UC-MSCs were infected with LV-sTNFRII-Fc, and the expression of EGFP were monitored under a fluorescence microscope. Representative pictures were shown 48 h after transfection. Scale bars: 500 μm. c Concentration of sTNFRII-Fc in the supernatant of sTNFRII-MSC. Supernatant of UC-MSC, EGFP-MSC and sTNFRII-MSC were collected after 48/72 h culture, and level of sTNFRII-Fc was determined using ELISA (n = 4). d Immunophenotypic profile of sTNFRII-MSC. Flow cytometry results showed that sTNFRII-MSC (red lines) were negative for CD45, HLA-DR and CD34, and positive for CD90, CD73 and CD105. Negative controls are represented by the green lines (n = 5). e Osteogenic capacity of sTNFRII-MSC. Alizarin Red S staining was used to evaluate the osteogenic capacity of sTNFRII-MSC, and the absorbance of eluent was determined at 550 nm for semiquantitation (n = 3–5). f Adipogenic capacity of sTNFRII-MSC. Oil Red staining was used to evaluate the adipogenic capacity of sTNFRII-MSC, and the absorbance of eluent was determined at 500 nm for semiquantitation (n = 3–5). g Chondrogenic capacity of sTNFRII-MSC. Alcian Blue staining was used to evaluate the chondrogenic capacity of sTNFRII-MSC, and the absorbance of eluent was determined at 600 nm for semiquantitation (n = 3–5). Data are presented as the mean ± SD values. ***P < 0.001